Drug intelligence / Profile preview

IPM-N001

Development stage
Preclinical
Lead developer
Huazhong University of Science and Technology
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

IPM-N001 is a bivalent, bimodal radiopharmaceutical precursor designed for targeting carbonic anhydrase IX (CAIX) and tumor hypoxia. Developed by researchers at the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, IPM-N001 was created by conjugating a hypoxia-sensitive 2-nitroimidazole (NI) moiety to the cyclic peptide DPI-4452 scaffold. When radiolabeled with gallium-68 to form [68Ga]Ga-IPM-N001, it serves as a PET/CT imaging radiotracer. In preclinical models of clear cell renal cell carcinoma (ccRCC), [68Ga]Ga-IPM-N001 demonstrated significantly enhanced tumor accumulation and superior tumor-to-background ratios compared to [68Ga]Ga-DPI-4452, without increasing physiological uptake in normal organs like the stomach and kidneys.

Other names
68Ga-IPM-N001Ga-IPM-N001Ga-IPM-N-001Ga-IPM-N 001[68Ga]Ga-IPM-N001
02

Identity

Drug type
Radiopharmaceuticals
Originator
Huazhong University of Science and Technology
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
clear-cell renal cell carcinoma (ccRCC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Huazhong University of Science and TechnologyOriginator · Lead developer
07

Competitive landscape

Drugs on the same target
35
Drugs in the lead indication
311

Lead indication: clear-cell renal cell carcinoma (ccRCC)

Most advanced in the lead indication

  1. acetazolamideApproved
  2. belzutifanApproved
  3. chlortalidonApproved
  4. dichlorphenamideApproved
  5. lenvatinibApproved

Beyond the preview

Go deeper on IPM-N001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPM-N001.

Work on IPM-N001? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call